Incidence of skin cancer development in pancreatic islet cell transplant patients: A retrospective study.

• Type of Material: Article
• Authors: Iviensan F. Manalo, Emory University; Valerie Truong, Emory University; Taryn DeGrazia, Emory University; Alexander L. Kollhoff, Augusta University; Hayley Braun, Emory University; Howa Yeung, Emory University; Travis Blalock, Emory University
• Language: English
• Date: 2021-04-01
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: © 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jdin.2021.01.004
• Title of Journal or Parent Work: JAAD Case Reports
• Volume: 3
• Start Page: 76
• End Page: 78
• Grant/Funding Information: None.
• Keywords: malignancy; risk; survivor; beta-cell replacement therapy; solid organ transplant; skin cancer; glycemic control
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Oncology

Abstract

To the Editor: Long-term survivors of solid organ transplants are at an increased risk of malignancies, most commonly skin cancer.1 While the risks of heart, lung, kidney, kidney-pancreas, liver, and hematopoietic cell transplant recipients are established, there are limited data on pancreatic islet cell transplant (ICT) recipients.2 ICT is an effective beta-cell replacement therapy performed to normalize glycemic control in patients with type 1 diabetes mellitus3 and/or as a treatment for patients with chronic pancreatitis.4 This study aims to identify and compare the incidence of nonmelanoma skin cancer (NMSC) in allogeneic and autologous ICT recipients.